A Response to the Brill Analysis for Proper Data Exclusivity Periods for Innovator Biologics

Posted: 1 Apr 2009

See all articles by John A. Vernon

John A. Vernon

University of North Carolina (UNC) at Chapel Hill; National Bureau of Economic Research (NBER)

Joseph H. Golec

University of Connecticut - Department of Finance

Date Written: March 31, 2009

Abstract

In this note we critique the Brill analysis for proper data exclusivity periods for innovator biologics.

Keywords: Follow on Biologics, Data Exclusivity, Biotech Financial Risk

JEL Classification: I11, K00

Suggested Citation

Vernon, John A. and Golec, Joseph, A Response to the Brill Analysis for Proper Data Exclusivity Periods for Innovator Biologics (March 31, 2009). Available at SSRN: https://ssrn.com/abstract=1371020 or http://dx.doi.org/10.2139/ssrn.1371020

John A. Vernon (Contact Author)

University of North Carolina (UNC) at Chapel Hill ( email )

102 Ridge Road
Chapel Hill, NC NC 27514
United States

National Bureau of Economic Research (NBER)

1050 Massachusetts Avenue
Cambridge, MA 02138
United States

Joseph Golec

University of Connecticut - Department of Finance ( email )

School of Business
2100 Hillside Road
Storrs, CT 06269
United States

Here is the Coronavirus
related research on SSRN

Paper statistics

Downloads
60
Abstract Views
416
rank
391,679
PlumX Metrics